AI-designed proteins open new paths for drugs and enzymes
This digest was compiled by AI from multiple sources — links to the originals are below.

AI tools are now designing proteins that never existed in nature, moving beyond evolution's constraints. A Nature review in April 2026 states that structural design problems are close to solved, shifting focus to what to design. Designed miniproteins showed 60-100% survival in mice against lethal snakebite toxins, demonstrating real therapeutic potential.
Key Facts
- Evolution has explored only a sliver of chemically possible proteins, leaving vast regions of protein space untouched.
- A Nature review in April 2026 by Wei Yang and colleagues states that long-standing structural design problems are close to solved.
- Designed miniproteins by Susana Vázquez Torres, David Baker, and Timothy Jenkins achieved 60-100% survival in mice given lethal snakebite toxin doses.
- The designed antivenom proteins are heat stable and can be produced in bacteria instead of livestock.
Protein Design Reversal
Nature runs protein creation forward: sequence produces structure, structure produces function. AI design runs the process backwards, starting with a desired function and working out the shape and sequence. Open-source tools like RFdiffusion, ProteinMPNN, and AlphaFold form the core pipeline for generating and validating new proteins. The April 2026 Nature review by Wei Yang and colleagues concludes the field's focus has shifted from how to design to what to design.
Snakebite Antivenom Proof
Snakebite kills more than 100,000 people annually, mostly in regions with limited treatment resources. Traditional antivenom, made by injecting horses with venom, often fails against three-finger toxins from cobras and mambas. A team led by Susana Vázquez Torres, David Baker, and Timothy Jenkins designed miniproteins that bind these toxins directly. In mice given lethal doses, survival ranged from 60% to 100% depending on toxin, dose, and timing of treatment. The designed proteins are heat stable and can be brewed in bacteria, a major advantage for regions without reliable refrigeration.
1 source
AI-designed proteins open new paths for drugs and enzymes


